Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Pituitary adenoma.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 1 | Pituitary adenoma |
Biomarker and diagnostic research for pituitary adenoma 5, multiple types has been reported in the published literature.
No clinical trials have been registered for pituitary adenoma 5, multiple types.
18 publications have been identified in PubMed for pituitary adenoma 5, multiple types. Research spans Clinical Trial Publication (33%), Diagnostic / Biomarker (17%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 6 | 33% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 10:55 PM UTC
Online Mendelian Inheritance in Man
Testing and diagnosis research
3 |
17% |
Research summaries | 3 | 17% |
Patient case studies | 2 | 11% |
Laboratory research | 2 | 11% |
Other research | 1 | 6% |
Disease patterns and progression | 1 | 6% |
de Lapiscina IM (2026). [PMID: 41912295](https://pubmed.ncbi.nlm.nih.gov/41912295/). *Vitam Horm*. [Review / Meta-Analysis]
Gorenshtein A (2026). [PMID: 40973910](https://pubmed.ncbi.nlm.nih.gov/40973910/). *J Imaging Inform Med*. [Diagnostic / Biomarker]
Sabouri M (2025). [PMID: 40205341](https://pubmed.ncbi.nlm.nih.gov/40205341/). *BMC neurology*. [Basic Science / Preclinical]
Hernández-Ramírez LC (2025). [PMID: 39908201](https://pubmed.ncbi.nlm.nih.gov/39908201/). *The Journal of clinical endocrinology and metabolism*. [Clinical Trial Publication]
Brown MR (2025). [PMID: 40152985](https://pubmed.ncbi.nlm.nih.gov/40152985/). *Epigenomics*. [Review / Meta-Analysis]
Delemer B (2025). [PMID: 41222780](https://pubmed.ncbi.nlm.nih.gov/41222780/). *Pituitary*. [Case Report / Case Series]
Lin W (2025). [PMID: 39720607](https://pubmed.ncbi.nlm.nih.gov/39720607/). *EClinicalMedicine*. [Clinical Trial Publication]
Turin CG (2025). [PMID: 40613749](https://pubmed.ncbi.nlm.nih.gov/40613749/). *Endocrine-related cancer*. [Epidemiology / Natural History]
Demirel-Ozbek E (2025). [PMID: 40979274](https://pubmed.ncbi.nlm.nih.gov/40979274/). *Neuro-ophthalmology (Aeolus Press)*. [Case Report / Case Series]
Chen D (2025). [PMID: 40307557](https://pubmed.ncbi.nlm.nih.gov/40307557/). *Nature*. [Basic Science / Preclinical]
AI-curated news mentioning pituitary adenoma 5, multiple types
Updated Aug 24, 2026
A recent study highlights the role of CXCR4 in the tumorigenesis of growth hormone-secreting pituitary adenoma stem-like cells. This transcriptional profiling could inform future clinical applications and therapeutic strategies.
A retrospective study evaluates the long-term outcomes of adjuvant proton radiotherapy for adults with residual pituitary adenoma. The findings contribute to understanding treatment efficacy and patient management strategies for this rare tumor.
A recent study published in PubMed highlights the clinicopathological features and outcomes of immature PIT-1 lineage tumors, identified as a high-risk subtype of pituitary neuroendocrine tumors according to WHO 2022. This research provides valuable insights into the characteristics and prognosis of this rare tumor type.